Gossamer Bio (id:8333 GOSS)
0.696 USD
Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 6:17:57 PM)
Exchange closed, opens in 15 hours 12 minutes
About Gossamer Bio
Market Capitalization 167.71M
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.
| Headquarters (address) |
3013 Science Park Road San Diego 92121 CA United States |
| Phone | 858 684 1300 |
| Website | https://www.gossamerbio.com |
| Employees | 135 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Ticker | GOSS |
| Exchange | NASDAQ Stock Exchange |
| Currency | USD |
| 52 week range | 0.499 - 1.60 |
| Market Capitalization | 167.71M |
| P/E trailing | -0.590 |
| P/E forward | -1.07 |
| Price/Sale | 1.59 |
| Price/Book | 3.10 |
| Beta | 1.96 |
| EPS | -0.250 |
| EPS United States (ID:6, base:3402) | 24.22 |